Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy

Rheumatology International

Volumn 30, Issue 6, 2010, Pages 817-819

  Sánchez Ramón, Silvia ^a   Ravell, Juan Carlos ^a   De La Torre, Inmaculada ^a   Montoro, María ^a   Rodríguez Mahou, Margarita ^a   Carreño Pérez, Luis ^a   Fernández Cruz, Eduardo ^a   López Longo, Francisco Javier ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Anti CD20; Dermatopolymyositis; Immunotherapy; Polyvalent immunoglobulin

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOMYOSITIS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MUSCLE, SKELETAL; REMISSION INDUCTION; SKIN; TIME; TREATMENT OUTCOME;

EID: 77951022140     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1000-x     Document Type: Article

References (11)

1. Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion- body myositis. N Engl J Med 325:1487-1498
2. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971-982. doi:10.1016/S0140-6736(03)14368-1 (Pubitemid 37159295)
3. Dalakas MC (2004) Molecular studies in autoimmune inXammatory muscle disorders. Curr Opin Neurol 17:561-567. doi:10.1097/00019052-200410000-00006 (Pubitemid 39410872)
4. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601-607. doi:10.1002/art.20849 (Pubitemid 40216325)
5. Chiappetta N, Steier J, Gruber B (2005) Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol 11:264-266. doi:10.1097/01.rhu. 0000182155.08982.60 (Pubitemid 41475695)
6. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M et al (2006) Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary ImmunodeWciency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(6):1483. doi:10.1016/ j.jaci.2006.04.014
7. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB (1993) EYcacy of intravenous immunoglobulin in the treatment of autoimmune haemolytic anemia: results in 73 patients. Am J Hematol 44(4):237-242. doi:10.1002/ajh.2830440404 (Pubitemid 23328620)
8. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C et al (1993) A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000. doi:10.1056/ NEJM199312303292704 (Pubitemid 24015043)
9. Dalakas MC (2006) The role of high-dose immune globulin intravenous in the treatment of dermatomyositis. Int Immunopharmacol 6:550-556. doi:10.1016/j.intimp.2005.11.016 (Pubitemid 43295460)
10. Umemura T, Kiyosawa K (2006) Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 45:747-748. doi:10.2169/internalmedicine.45. 0158 (Pubitemid 44111014)
11. Kimby E (2005) Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 31:456-473. doi:10.1016/j.ctrv.2005.05.007 (Pubitemid 41536169)